ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,618.26
      0.00%
      US Tech 100
      19,260.80
      2.14%
      Dow Jones
      41,503.10
      0.00%
      Brent Oil
      73.97
      2.20%
      Bitcoin
      62,977.78
      2.12%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Rigel Pharmaceuticals Inc (RIGL) Quote

      Rigel Pharmaceuticals Inc

      Rigel Pharmaceuticals Inc (RIGL)

      NASDAQ
      13.63
      -0.05
      (-0.37%)
      Closed September 18 4:00PM
      Delayed by 15 minutes
      13.62
      -0.01
      ( -0.07% )
      Pre Market: 8:12AM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      13.62
      Bid
      13.00
      Ask
      13.63
      Volume
      100
      0.00 Day's Range 0.00
      7.12 52 Week Range 17.30
      Market Cap
      239.644M
      Previous Close
      13.63
      Open
      -
      Last Trade
      100
      @
      13.62
      (formt)
      Last Trade Time
      08:12:19
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      134,513
      Shares Outstanding
      17,594,977
      Dividend Yield
      -
      PE Ratio
      -9.56
      Earnings Per Share (EPS)
      -1.43
      Revenue
      116.88M
      Net Profit
      -25.09M

      About Rigel Pharmaceuticals Inc

      Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.rigel.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was $13.63. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of $ 7.12 to $ 17.30.

      Rigel Pharmaceuticals currently has 17,594,977 shares outstanding. The market capitalization of Rigel Pharmaceuticals is $239.82 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -9.56.

      Ask ADVFN Intelligence (AI)

      RIGL Latest News

      More News

      FeaturedElement79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership

      22 hours ago

      Rigel to Present at the 2024 Cantor Global Healthcare Conference

      Rigel to Present at the 2024 Cantor Global Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 12, 2024 /PRNewswire/ -- Rigel...

      September 12 2024
      PR Newswire (US)

      Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

      Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024 First trial in Rigel's...

      September 05 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      September 04 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      September 04 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      September 03 2024
      Edgar (US Regulatory)

      Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan

      Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 3, 2024 Kissei gains...

      September 03 2024
      PR Newswire (US)

      Rigel to Participate in Upcoming September Investor Conferences

      Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 /PRNewswire/ -- Rigel...

      August 29 2024
      PR Newswire (US)

      Form EFFECT - Notice of Effectiveness

      August 12 2024
      Edgar (US Regulatory)

      Form S-8 - Securities to be offered to employees in employee benefit plans

      August 06 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.64.6082949308813.0214.212.769912913.4292933CS
      41.149.1346153846212.4814.2129717513.25851712CS
      125.8274.61538461547.814.27.484313451310.6634716CS
      260.221.6417910447813.415.057.484395316310.67446453CS
      522.9227.289719626210.717.37.12104659611.20385495CS
      156-24.48-64.251968503938.139.056.4227494214.67845207CS
      260-3.38-19.882352941217556.4252473822.80268178CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TBIOTelesis Bio Inc
      $ 4.15
      (205.15%)
      		13.84M
      ZEOZeo Energy Corporation
      $ 2.93
      (157.02%)
      		5.71M
      XCURExicure Inc
      $ 5.57
      (143.23%)
      		4.73M
      VEROVenus Concept Inc
      $ 0.879
      (74.93%)
      		6.24M
      ACHLAchilles Therapeutics PLC
      $ 1.03
      (45.07%)
      		8.14M
      PGNYProgyny Inc
      $ 18.51
      (-24.26%)
      		152.5k
      HAOHaoxi Health Technology Ltd
      $ 2.32
      (-22.67%)
      		27.73k
      VVOSVivos Therapeutics Inc
      $ 3.25
      (-21.31%)
      		700.08k
      WBUYWeBuy Global Ltd
      $ 0.148
      (-19.70%)
      		1.89M
      ATMCAlphaTime Acquisition Corporation
      $ 9.00
      (-19.64%)
      		10
      FRGTFreight Technologies Inc
      $ 0.1593
      (28.57%)
      		34.94M
      MAXNMaxeon Solar Technologies Ltd
      $ 0.0998
      (9.79%)
      		19.52M
      TBIOTelesis Bio Inc
      $ 4.15
      (205.15%)
      		13.84M
      SQQQProShares UltraPro Short QQQ
      $ 7.86
      (-6.43%)
      		10.31M
      ACHLAchilles Therapeutics PLC
      $ 1.03
      (45.07%)
      		8.14M

      RIGL Discussion

      View Posts
      dcaf7 dcaf7 5 months ago
      Titles of olutasidenib presentations at ASCO:
      1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
      2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
      3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
      👍️0
      Monksdream Monksdream 5 months ago
      RIGL under $2
      👍️0
      Monksdream Monksdream 6 months ago
      RIGL under $2
      👍️0
      dcaf7 dcaf7 6 months ago
      Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
      https://pubmed.ncbi.nlm.nih.gov/38538632/
      👍️0
      dcaf7 dcaf7 6 months ago
      Good read on Olutasidenib
      https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
      Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
      👍️0
      dcaf7 dcaf7 7 months ago
      Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
      FEBRUARY 22, 2024 7:50AM EST
      GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
      Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
      GAVRETO generated ~$28M in U.S. net product sales in 2023
      👍️0
      bme bme 1 year ago
      Rigl should be VTGN (Today) one day.
      👍️0
      bme bme 1 year ago
      Yeah. Should be good Q.
      👍️0
      TucsonPhil TucsonPhil 1 year ago
      Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
      👍️0
      bme bme 1 year ago
      Better be good.
      👍️0
      bme bme 1 year ago
      Ugly.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      base
      👍️0
      bme bme 1 year ago
      What a shoot! Amazing.
      👍️0
      bme bme 1 year ago
      The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
      1. What else should we expect as for the rev?
      2. Result of phase 3 of Fostamatinib3 COVID 19?
      3. Status of Fostamatinib-ACTIV4 COVID 19?
      4. Partnered Programs?
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice fins
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      gem
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      gem
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      easy
      👍️0
      bme bme 1 year ago
      Nice spike AH today.
      👍️0
      bme bme 1 year ago
      Higher low higher low.... next leg is North.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
      👍️0
      bme bme 1 year ago
      acting wild atm, but still healthy.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      bme bme 1 year ago
      Nice & Healthy.
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      quite the dip
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      ready
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      ready
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      red to green
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      red to green
      👍️0
      bme bme 1 year ago
      Wonderful!
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      beauty
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      bme bme 2 years ago
      Expect Q4 filing this week?
      👍️0
      bme bme 2 years ago
      Be seeing that. Lot of 1.95 transactions so far
      👍️0
      TucsonPhil TucsonPhil 2 years ago
      Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
      👍️0
      bme bme 2 years ago
      SP should be a lot higher since the Q4 revenue is more than double from last year...
      👍️0
      Welldoctor Welldoctor 2 years ago
      Apparently insider buying reported on ST. Take it for what it’s worth.
      👍️0
      Welldoctor Welldoctor 2 years ago
      RIGL news out
      👍️0
      bme bme 2 years ago
      Looks like it will poke thru & bye bye 1 today.
      👍️0
      doesitreallymatter doesitreallymatter 2 years ago
      Just like ABQQ. Right?
      👍️0
      subslover subslover 2 years ago
      You are 1/2 way there!!!!
      👍️0
      KngmAz KngmAz 2 years ago
      Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
      👍️0
      KngmAz KngmAz 2 years ago
      This is a $10.00 per share stock in the very near future - EASILY!!
      👍️0
      Alaska40 Alaska40 2 years ago
      I just bought in. Seems like a good run could come in the near future.
      👍️0
      subslover subslover 2 years ago
      Consolidating nicely on Continuation from last week!
      👍️0
      bcapps66 bcapps66 2 years ago
      LOL!
      👍️0
      THEMASTERS_SON THEMASTERS_SON 2 years ago
      GIVE ME MY $2DOLLAS…YA BUM
      👍️0

      Your Recent History

      NASDAQ
      RIGL
      Rigel Pharmaceuticals
      Delayed Upgrade Clock